MEI Pharma, Inc.
|Company Name||MEI Pharma, Inc.|
On May 13, 2022, after the market closed, MEI Pharma announced that it would restate certain financial results because "revenue was overstated in some quarters and understated in other quarters in the Company's financial statements during 2020 and 2021." The errors were due to improper revenue recognition from its license, development, and commercialization agreement with Kyowa Kirin Co., Ltd.
On this news, MEI Pharma’s stock fell $0.04, or 7.2%, to close at $0.48 per share on May 16, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your MEI Pharma, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.